Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

NCT07133802 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

6680

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of Influenza

Interventions

BIOLOGICAL: Placebo Group
BIOLOGICAL: Test Group

Sponsor

Changchun BCHT Biotechnology Co.

Collaborators

[object Object]
[object Object]
[object Object]